Article citationsMore>>
Gridelli, C., Manegold, C., Mali, P., Reck, M., Portalone, L., Castelnau, O., Stahel, R., Betticher, D., Pless, M., Pons, J.T., Aubert, D., Burillon, J.P., Parlier, Y. and De Marinis, F. (2004) Oral Vinorelbine Given as Monotherapy to Advanced, Elderly NSCLC Patients: A Multicentre Phase II Trial. European Journal of Cancer, 40, 2424-2431.
https://doi.org/10.1016/j.ejca.2004.07.028
has been cited by the following article:
-
TITLE:
Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type
AUTHORS:
Amen Hamdy Zaky, Ahmed Refaat Abd Elzaher, Ola Nabih
KEYWORDS:
Lung Cancer, Maintenance Chemotherapy, Vinorelbine, EGFR-Wild Type
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.10 No.12,
December
10,
2019
ABSTRACT:
Background: This study was performed to evaluate the efficacy
and safety of switch maintenance therapy with oral vinorelbine in advanced
non-small cell lung cancer (NSCLC) with adenocarcinoma limited to epidermal
growth factor receptor (EGFR) wild type. Materials
and Methods: In this single randomized
trial, patients with advanced stage (IIIB and IV) NSCLC with adenocarcinoma
EGFR wild-type status, treated with 6 cycles of platinum based chemotherapy.
Patients did not show progression after first-line chemotherapy were randomly
assigned to receive switch maintenance with vinorelbine (80 mg/m2,
day 1, 8) (group I) or the best supportive care until disease progression
(group II). Results: The median progression free survival (PFS) was 9.7
months for group I versus 5.7 months for group II with statistically
significant difference between both groups [HR = 1.15; 95% CI 1.19 to 1.49; P
value = 0.002], while the median overall survival (OS) was 13.2 months for
group I versus 11.9 months for group II with no statistically significant
differences between both groups [HR = 1.24; 95% CI 1.05 to 1.46; P value = 0.
3]. The patients who received oral vinorelbine had tolerable toxicity profile. Conclusion: Switch maintenance therapy with oral vinorelbine,
though improve PFS, did not improve OS in patients with NSCLC with
adenocarcinoma EGFR wild type.
Related Articles:
-
Kan Wu, Laner Wu, Zhenkun Huang, Yong Jiang, Yun Ma
-
Tiama Guy Nicaise Ballet, Kôkôh Rose Effebi, Olga Yolande Aké Ako, Yapo Habib Kpidi, Ossey Bernard Yapo
-
Hervé A. N’cho, Innocent K. Kouame, Kouadio Koff, Lazare K. Kouassı, Séraphin K. Konan, Ruth Baï, Andrei Sandu, Ion Sandu
-
Jai Dev Chandel, Nand Lal Singh
-
Sangaré Naminata, Kouassi Edith Kwa-Koffi, Kouassi Aka Marcel, Yao Koffi Marcellin